Their products are used in cancer and women's health applications, such as cervical cancer screening, menstrual bleeding treatment, early-stage breast cancer radiation treatment, and malignant brain tumors radiation treatment applications. Cytyc serves customers in Canada, Europe, and Asia/Pacific markets. In 2007, Hologic acquired Cytyc in a cash-and-stock deal worth $6.2 billion, with the aim of driving enhanced growth and value creation. The acquisition was expected to add 10 cents to Hologic's bottom line in the first year.